Change in Director / Key Managerial Personnel
Nature of change: Cessation of Senior Management Personnel (SMP) association.
Name and DIN of the individual: Mr. Sendhil Pani. DIN not disclosed in the filing.
Effective date and tenure: Ceased to be SMP with effect from October 2, 2026. The change arose due to the completion of contractual arrangements between the Company and Mr. Sendhil Pani.
Brief profile and relevant qualifications: Not disclosed in the annexure (marked 'Not Applicable').
Confirmation of eligibility: The change is communicated pursuant to and in compliance with Regulation 30 read with Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically referencing Regulation 16(1)(d).
Relationship with other directors: Not disclosed (marked 'Not Applicable' in the annexure).
Previous KMP: Mr. Sendhil Pani was the 'Managing Director' of Sudeep Pharma USA Inc., a Wholly Owned Subsidiary of Sudeep Pharma Limited, and was earlier appointed/designated as a Senior Management Personnel (SMP) of Sudeep Pharma Limited.
Key Financial or Operational Approvals
This section is not applicable to the current disclosure, which solely concerns a management change.
Strategic or Business Context
This section is not applicable to the current disclosure, which does not contain business commentary or outlook.
Any Other Material Information
This intimation is a regulatory compliance disclosure made to the National Stock Exchange of India Limited (Scrip Symbol: SUDEEPPHRM) and BSE Limited (Scrip Code: 544619).
The formal communication is signed by Dimple Mehta, Company Secretary & Compliance Officer (Membership No.: F13184).
The disclosure is made with reference to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.